ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
By virtue of their intrinsic immunomodulatory properties, mesenchymal stromal cells (MSCs) represent a promising therapeutic tool for immune-related disorders. Research findings support that MSCs are involved in complex inflammatory pathologies by interacting with local immune cells. In addition to their immunomodulation ability, MSCs also contribute to cell-mediated tissue regeneration due to their potential for multilineage differentiation. However, despite their accessibility, clinical translation of MSCs faces challenges, including their inherent heterogeneity, transient therapeutic effects, and microenvironment-dependent functionality. This review provides an overview of current advances in MSC-based therapies for immune-related disorders, emphasizing Phase III and IV clinical trials and therapies approved by global regulatory agencies. Additionally, we highlight innovative engineering strategies designed to address the limitations of MSCs while enhancing their immunomodulatory capabilities. These approaches include: (1) cell pre-treatment and genetic modification to improve therapeutic efficacy; (2) biomaterial-mediated delivery systems for targeted sites; (3) MSC-derived extracellular vesicle (EV)-based therapeutics to amplify paracrine signaling; (4) induced pluripotent stem cell (iPSC)-derived MSCs to overcome donor variability. By integrating these methodologies with ongoing clinical approaches, this review underscores the potential of engineered MSC immunomodulation in addressing inflammatory pathologies, bridging the gap between basic research and clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.